Chong Kun Dang Pharmaceutical Total Assets
Chong Kun Dang Pharmaceutical total assets. Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) holds total assets worth ₩1.83 Trillion KRW (≈ $1.24 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 185750 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Chong Kun Dang Pharmaceutical (2016–2025)
Total assets of Chong Kun Dang Pharmaceutical from 2016 to 2025. This chart illustrates how Chong Kun Dang Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See 185750 share price today for real-time trading data and today's change.
Chong Kun Dang Pharmaceutical - Asset Composition Analysis
Chong Kun Dang Pharmaceutical Total Assets Breakdown (December 2025)
Chong Kun Dang Pharmaceutical total assets breakdown as of December 2025. Chong Kun Dang Pharmaceutical's total assets of ₩1.83 Trillion consist of 60.7% current assets and 39.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 12.0% |
| Accounts Receivable | ₩265.84 Billion | 14.8% |
| Inventory | ₩428.65 Billion | 23.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩107.51 Billion | 6.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Chong Kun Dang Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Chong Kun Dang Pharmaceutical to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chong Kun Dang Pharmaceutical's current assets represent 60.7% of total assets in 2025, an increase from 52.8% in 2016.
- Cash Position: Cash and equivalents constituted 12.0% of total assets in 2025, up from 3.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 23.8% of total assets.
Chong Kun Dang Pharmaceutical Competitors by Total Assets
Key competitors of Chong Kun Dang Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
Chong Kun Dang Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 2.50 | 1.86 |
| Quick Ratio | 1.15 | 1.51 | 1.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩522.64 Billion | ₩592.87 Billion | ₩268.45 Billion |
Chong Kun Dang Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Chong Kun Dang Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 23.4% |
| Total Assets | ₩1.80 Trillion |
| Market Capitalization | $533.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chong Kun Dang Pharmaceutical's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Chong Kun Dang Pharmaceutical's assets grew by 23.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chong Kun Dang Pharmaceutical (2016–2025)
The table below shows the annual total assets of Chong Kun Dang Pharmaceutical from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.80 Trillion ≈ $1.22 Billion |
+23.41% |
| 2024-12-31 | ₩1.46 Trillion ≈ $988.58 Million |
+4.02% |
| 2023-12-31 | ₩1.40 Trillion ≈ $950.41 Million |
+24.67% |
| 2022-12-31 | ₩1.12 Trillion ≈ $762.32 Million |
+7.47% |
| 2021-12-31 | ₩1.05 Trillion ≈ $709.33 Million |
+10.61% |
| 2020-12-31 | ₩946.33 Billion ≈ $641.32 Million |
+18.09% |
| 2019-12-31 | ₩801.35 Billion ≈ $543.06 Million |
+12.63% |
| 2018-12-31 | ₩711.49 Billion ≈ $482.17 Million |
+5.06% |
| 2017-12-31 | ₩677.21 Billion ≈ $458.93 Million |
+5.53% |
| 2016-12-31 | ₩641.70 Billion ≈ $434.87 Million |
-- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more